128 related articles for article (PubMed ID: 9443626)
1. All-trans-retinoic acid modulation of drug-metabolizing enzyme activities: investigation with selective metabolic drug probes.
Adedoyin A; Stiff DD; Smith DC; Romkes M; Bahnson RC; Day R; Hofacker J; Branch RA; Trump DL
Cancer Chemother Pharmacol; 1998; 41(2):133-9. PubMed ID: 9443626
[TBL] [Abstract][Full Text] [Related]
2. Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects.
Frye RF; Branch RA
Br J Clin Pharmacol; 2002 Feb; 53(2):155-62. PubMed ID: 11851639
[TBL] [Abstract][Full Text] [Related]
3. Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail.
Adedoyin A; Frye RF; Mauro K; Branch RA
Br J Clin Pharmacol; 1998 Sep; 46(3):215-9. PubMed ID: 9764961
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome p450 retinoic acid 4-hydroxylase inhibitors: potential agents for cancer therapy.
Njar VC
Mini Rev Med Chem; 2002 Jun; 2(3):261-9. PubMed ID: 12370067
[TBL] [Abstract][Full Text] [Related]
5. All-Trans Retinoic Acid Activity in Acute Myeloid Leukemia: Role of Cytochrome P450 Enzyme Expression by the Microenvironment.
Su M; Alonso S; Jones JW; Yu J; Kane MA; Jones RJ; Ghiaur G
PLoS One; 2015; 10(6):e0127790. PubMed ID: 26047326
[TBL] [Abstract][Full Text] [Related]
6. In vivo modulation of CYP enzymes by quinidine and rifampin.
Branch RA; Adedoyin A; Frye RF; Wilson JW; Romkes M
Clin Pharmacol Ther; 2000 Oct; 68(4):401-11. PubMed ID: 11061580
[TBL] [Abstract][Full Text] [Related]
7. all-trans-Retinoic acid-induced expression and regulation of retinoic acid 4-hydroxylase (CYP26) in human promyelocytic leukemia.
Ozpolat B; Mehta K; Tari AM; Lopez-Berestein G
Am J Hematol; 2002 May; 70(1):39-47. PubMed ID: 11994980
[TBL] [Abstract][Full Text] [Related]
8. Regulation of a highly specific retinoic acid-4-hydroxylase (CYP26A1) enzyme and all-trans-retinoic acid metabolism in human intestinal, liver, endothelial, and acute promyelocytic leukemia cells.
Ozpolat B; Mehta K; Lopez-Berestein G
Leuk Lymphoma; 2005 Oct; 46(10):1497-506. PubMed ID: 16194896
[TBL] [Abstract][Full Text] [Related]
9. Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes.
Frye RF; Matzke GR; Adedoyin A; Porter JA; Branch RA
Clin Pharmacol Ther; 1997 Oct; 62(4):365-76. PubMed ID: 9357387
[TBL] [Abstract][Full Text] [Related]
10. Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases.
Njar VC; Gediya L; Purushottamachar P; Chopra P; Vasaitis TS; Khandelwal A; Mehta J; Huynh C; Belosay A; Patel J
Bioorg Med Chem; 2006 Jul; 14(13):4323-40. PubMed ID: 16530416
[TBL] [Abstract][Full Text] [Related]
11. Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: evidence for specificity toward P-450 2E1.
Kharasch ED; Hankins DC; Jubert C; Thummel KE; Taraday JK
Drug Metab Dispos; 1999 Jun; 27(6):717-23. PubMed ID: 10348802
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of all-trans-retinoic acid in hormone-refractory prostate cancer: a clinical trial with detailed pharmacokinetic analysis.
Trump DL; Smith DC; Stiff D; Adedoyin A; Day R; Bahnson RR; Hofacker J; Branch RA
Cancer Chemother Pharmacol; 1997; 39(4):349-56. PubMed ID: 9025776
[TBL] [Abstract][Full Text] [Related]
13. Effect of NADPH-cytochrome P450 reductase on all-trans-retinoic acid efficacy and cytochrome P450 26A1 expression in human myeloid leukaemia HL-60 cells.
Hu L; Lv JF; Zhuo W; Zhang CM; Zhou HH; Fan L
J Pharm Pharmacol; 2016 Sep; 68(9):1193-202. PubMed ID: 27366899
[TBL] [Abstract][Full Text] [Related]
14. P450-dependent enzymes as targets for prostate cancer therapy.
De Coster R; Wouters W; Bruynseels J
J Steroid Biochem Mol Biol; 1996 Jan; 56(1-6 Spec No):133-43. PubMed ID: 8603034
[TBL] [Abstract][Full Text] [Related]
15. Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
Patel JB; Huynh CK; Handratta VD; Gediya LK; Brodie AM; Goloubeva OG; Clement OO; Nanne IP; Soprano DR; Njar VC
J Med Chem; 2004 Dec; 47(27):6716-29. PubMed ID: 15615521
[TBL] [Abstract][Full Text] [Related]
16. All-trans-retinoic acid 4-hydroxylation in human liver microsomes: in vitro modulation by therapeutic retinoids.
Nadin L; Murray M
Br J Clin Pharmacol; 1996 Jun; 41(6):609-12. PubMed ID: 8799529
[TBL] [Abstract][Full Text] [Related]
17. An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A).
Palmer JL; Scott RJ; Gibson A; Dickins M; Pleasance S
Br J Clin Pharmacol; 2001 Nov; 52(5):555-61. PubMed ID: 11736864
[TBL] [Abstract][Full Text] [Related]
18. Participation of CYP2C8 in retinoic acid 4-hydroxylation in human hepatic microsomes.
Nadin L; Murray M
Biochem Pharmacol; 1999 Oct; 58(7):1201-8. PubMed ID: 10484078
[TBL] [Abstract][Full Text] [Related]
19. Liver disease selectively modulates cytochrome P450--mediated metabolism.
Frye RF; Zgheib NK; Matzke GR; Chaves-Gnecco D; Rabinovitz M; Shaikh OS; Branch RA
Clin Pharmacol Ther; 2006 Sep; 80(3):235-45. PubMed ID: 16952490
[TBL] [Abstract][Full Text] [Related]
20. Effect of cytochrome P450 inhibitors (diethyl dithiocarbamate, ketoconazole and grapefruit juice) on the pharmacokinetics of all-trans-retinoic acid.
Saadeddin A; Torres-Molina F; Cárcel-Trullols J; Araico A; Peris JE
Farmaco; 2004 Sep; 59(9):697-702. PubMed ID: 15337435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
